AMRN
USDAmarin Corporation plc
即時價格
價格圖表
關鍵指標
市場指標
開盤
$15.670
最高
$15.745
最低
$15.110
交易量
0.06M
公司基本面
市值
326.7M
行業
Drug Manufacturers - General
國家
Ireland
交易統計
平均交易量
0.10M
交易所
NCM
貨幣
USD
52週範圍
AI分析報告
最後更新: 2025年11月5日AMRN Analysis: Navigating Short-Term Volatility in Amarin Corporation Shares
Key Takeaways
- Recent technical indicators show bullish momentum but conflicting signals
- Q3 2025 results triggered sharp price drop, reflecting operational uncertainty
- Stock trades at historical discount to 52-week highs but risks remain
- Fundamental risks outweigh short-term value opportunities
Recent News Impact
Positive Developments
- Scientific Validation (Nov 3, 2025) New analyses presented at AHA Scientific Sessions reinforce Vascepa’s clinical data consistency and mechanism of action.
- FDA Labeling Support (Oct 27, 2025) Company publicly aligned with FDA’s fenofibrate labeling revision, potentially strengthening Vascepa’s competitive differentiation.
Mixed Earnings Release (Oct 29, 2025)
Q3 results highlighted international expansion progress but triggered a 10% single-day crash (from $18.50 to $16.70), suggesting market skepticism about execution risks in the new commercialization model.
相關新聞
Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025
DUBLIN and BRIDGEWATER, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced it will be presenting new
Amarin Reports Third Quarter 2025 Financial Results
Company completes transition to fully partnered commercialization model across all international markets Q3 2025 performance reflects initial impact of new approach to Europe, ongoing expansion of Rest-of-World demand,
Amarin Issues Statement Supporting FDA's Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit
DUBLIN and BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care worldwide, today issued the following statement
Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, in collaboration with its Canadian
AI預測Beta
AI推薦
更新於: 2025年11月10日 下午01:07
58.4% 信心度
風險與交易
入場點
$15.36
獲利了結
$15.93
止損
$14.06
關鍵因素
相關股票
保持更新
設定價格提醒，獲取AI分析更新和即時市場新聞。